Additional positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine
Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated additional positive proof-of-concept also in a metastatic outgrowth therapeutic tumor mice model. These data support the already established preclinical proof-of-concept results announced in December 2021
Gasum and Loiste Energia have entered into an extensive partnership agreement on energy management services with effect from the beginning of April 2022. By outsourcing its energy market process and systems to Gasum, Loiste aims to achieve better returns from the electricity markets and can also focus on its core business.Gasum and Loiste’s partnership extensively covers energy management services such as sales of electricity production, electricity market portfolio management and brokering services,
Global coating solutions provider Teknos has published its non-financial report for 2021. By publishing non-financial information, Teknos strives to provide transparency into the progress of its sustainability actions.
The non-financial report describes the progress of Teknos’ sustainability actions defined in the Teknos Corporate Social Responsibility (CSR) Program. Teknos’ CSR Program aims to create long-term added value to Teknos' stakeholders and has four focus areas: sustainable solutions and services, responsible operations and supply chain, people development, and future
